IP Library › Granted Patent US 12,421,312
Granted Patent B2
US 12,421,312 · App. 17/061,998 · Granted Sep 23, 2025

Anti-PD-L1 antibodies and antibody-drug conjugates

Inventors: Byron Hua Kwan (Bothell, WA); Heather Van Epps (Bothell, WA); Andrew Waight (Bothell, WA); Scott Jeffrey (Snohomish, WA); Ryan Lyski (Lynnwood, WA)
Assignee: Seagen Inc.
C07K16/2827A61K47/6801A61K47/68031A61K47/68037A61P35/00A61K2039/505
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,421,312
App. No.
17/061,998
Granted
Sep 23, 2025
Kind
B2
Abstract

Provided are novel anti-PD-L1 antibodies and antibody-drug conjugates and methods of using such anti-PD-L1 antibodies and antibody-drug conjugates to treat cancer.

Claims (56)

1. An antibody or antigen-binding fragment thereof that specifically binds to the human PD-L1 protein, wherein the antibody comprises the heavy chain CDR sequences of SEQ ID NOs: 13-15 and the light chain CDR sequences of SEQ ID NOs: 16-18.

2. The antibody of claim 1 , wherein the antibody further exhibits a total internalization that is higher than the total internalization of an antibody comprising the heavy chain variable region sequence of SEQ ID NO: 1 and the light chain variable region sequence of SEQ ID NO: 2.

3. The antibody of claim 1 , wherein the antibody further exhibits an IC50 that is higher than the IC50 of an antibody comprising the heavy chain variable region sequence of SEQ ID NO: 1 and the light chain variable region sequence of SEQ ID NO: 2.

4. The antibody of claim 3 , wherein the antibody is conjugated to monomethyl auristatin E (MMAE), and wherein the IC50 is between 3 ng/mL and 20 ng/mL in an MDA-MB-231 cell line.

5. The antibody of claim 3 , wherein the antibody is conjugated to camptothecin, and wherein the IC50 is between 15 ng/mL and 55 ng/mL in an MDA-MB-231 cell line.

6. The antibody of claim 1 , wherein the antibody comprises the heavy chain variable region sequence of SEQ ID NO: 11 and the light chain variable region sequence of SEQ ID NO: 12.

7. The antibody of claim 1 , wherein the antibody comprises the heavy chain sequence of SEQ ID NO: 9 and the light chain sequence of SEQ ID NO: 10.

8. The antibody of claim 1 , wherein the fragment is a Fab, Fab′, F(ab′) 2 , Fab′-SH, Fv, diabody, linear antibody, or single-chain antibody fragment.

9. The antibody of claim 1 , wherein the antibody contains L234A and L235A mutations in the heavy chain of the antibody.

10. The antibody of claim 1 , wherein the heavy chain constant region is of the IgG1 isotype.

11. The antibody of claim 1 , wherein the antibody is a humanized or chimeric antibody.

12. The antibody of claim 1 , wherein the antibody is conjugated to a cytotoxic agent via a linker.

13. The antibody of claim 12 , wherein the antibody is conjugated to monomethyl auristatin E (MMAE).

14. The antibody of claim 13 , wherein the antibody is conjugated to MMAE via an enzyme-cleavable linker unit.

15. The antibody of claim 14 , wherein the enzyme-cleavable linker unit comprises a Val-Cit linker.

16. The antibody of claim 12 , wherein the antibody is conjugated to MMAE via a linker forming an antibody-drug conjugate having the structure:

wherein Ab represents the antibody and p ranges from 2 to 10.

17. The antibody of claim 16 , wherein p is 4.

18. The antibody of claim 16 , wherein p is 8.

19. The antibody of claim 12 , wherein the antibody is conjugated to camptothecin.

20. The antibody of claim 19 , wherein the antibody is conjugated to camptothecin via an enzyme-cleavable linker unit.

21. The antibody of claim 20 , wherein the enzyme-cleavable linker unit comprises a Val-Lys-Gly linker.

22. The antibody of claim 19 , wherein the antibody is conjugated to camptothecin via a linker forming an antibody-drug conjugate having the structure:

wherein Ab represents the antibody and p ranges from 2 to 10.

23. The antibody of claim 22 , wherein p is 4.

24. The antibody of claim 22 , wherein p is 8.

25. A pharmaceutical composition that comprises a therapeutically effective amount of the antibody of claim 1 and a pharmaceutically acceptable excipient.

26. A method of treating cancer in a subject, comprising administering to the subject the antibody of claim 1 .

27. The method of claim 26 , wherein the subject is a human subject.

28. The method of claim 26 or 27 , wherein the cancer is melanoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck cancer, triple negative breast cancer (TNBC), ovarian cancer, urothelial cancer, hepatocellular carcinoma (HCC), gastric cancer, or cervical cancer.

29. A nucleic acid encoding the antibody as defined by claim 1 .

30. A vector comprising the nucleic acid of claim 29 .

31. A host cell comprising the nucleic acid of claim 29 .

32. The host cell of claim 31 , wherein the host cell is a Chinese hamster ovary (CHO) cell.

33. A method of producing an antibody or antigen-binding fragment thereof that specifically binds to the human PD-L1 protein, comprising culturing the host cell of claim 31 or 32 under a condition suitable for production of the antibody.

34. A method of producing an antibody drug-conjugate that specifically binds to the human PD-L1 protein, comprising culturing the host cell of claim 31 or 32 under a condition suitable for production of the antibody; and conjugating the antibody to a cytotoxic agent.

35. The method of claim 34 , wherein the cytotoxic agent is MMAE or camptothecin.

36. An antibody-drug conjugate comprising an anti-PD-L1 antibody conjugated to a cytotoxic agent via a linker, wherein the antibody comprises the heavy chain variable region sequence of SEQ ID NO: 11 and the light chain variable region sequence of SEQ ID NO: 12.

37. The antibody-drug conjugate of claim 36 , wherein the cytotoxic agent is MMAE.

38. A composition comprising the antibody-drug conjugate of claim 36 .

39. The antibody-drug conjugate of claim 36 , wherein the antibody comprises the heavy chain sequence of SEQ ID NO: 9 and the light chain sequence of SEQ ID NO: 10.

40. The antibody-drug conjugate of claim 39 , wherein the cytotoxic agent is MMAE.

41. A composition comprising the antibody-drug conjugate of claim 39 .

42. An antibody-drug conjugate comprising an anti-PD-L1 antibody conjugated to vcMMAE, wherein the antibody comprises the heavy chain variable region sequence of SEQ ID NO: 11 and the light chain variable region sequence of SEQ ID NO: 12, and wherein the antibody-drug conjugate has the structure:

wherein Ab represents the antibody and p ranges from 2 to 10.

43. The antibody-drug conjugate of claim 42 , wherein p is 4.

44. An antibody-drug conjugate comprising an anti-PD-L1 antibody conjugated to vcMMAE, wherein the antibody comprises the heavy chain sequence of SEQ ID NO: 9 and the light chain sequence of SEQ ID NO: 10, and wherein the antibody-drug conjugate has the structure:

wherein Ab represents the antibody and p ranges from 2 to 10.

45. The antibody-drug conjugate of claim 44 , wherein p is 4.

46. A method of treating cancer in a subject, comprising administering to the subject the antibody of claim 12 .

47. A method of treating cancer in a subject, comprising administering to the subject an antibody-drug conjugate comprising an anti-PD-L1 antibody conjugated to vcMMAE, wherein the antibody comprises the heavy chain variable region sequence of SEQ ID NO: 11 and the light chain variable region sequence of SEQ ID NO: 12, and wherein the antibody-drug conjugate has the structure:

wherein Ab represents the antibody and p ranges from 2 to 10.

48. The method of claim 47 , wherein p is 4.

49. The method of claim 47 , wherein the antibody comprises the heavy chain sequence of SEQ ID NO: 9 and the light chain sequence of SEQ ID NO: 10.

50. An antibody that specifically binds to the human PD-L1 protein, wherein the antibody comprises the heavy chain variable region sequence of SEQ ID NO: 11 and the light chain variable region sequence of SEQ ID NO: 12.

51. An antibody that specifically binds to the human PD-L1 protein, wherein the antibody comprises the heavy chain sequence of SEQ ID NO: 9 and the light chain sequence of SEQ ID NO: 10.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2021
From: JEFFREY, SCOTT; LYSKI, RYAN
To: SEAGEN INC.
Reel/Frame 055784/0295 →
CHANGE OF NAME Recorded Oct 21, 2020
From: SEATTLE GENETICS, INC.
To: SEAGEN INC.
Reel/Frame 054174/0595 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2020
From: KWAN, BYRON HUA; VAN EPPS, HEATHER; WAIGHT, ANDREW
To: SEATTLE GENETICS, INC.
Reel/Frame 054002/0299 →
Continuity (2)
Provisional Application 62910988 · Oct 4, 2019
Related Publication 20210101982A1 · Apr 8, 2021
References Cited (113)
US 4474893A · Reading · 1984 [cited by applicant]
US 4714681A · Reading · 1987 [cited by applicant]
US 4880935A · Thorpe · 1989 [cited by applicant]
US 4925648A · Hansen et al. · 1990 [cited by applicant]
US 5122368A · Greenfield et al. · 1992 [cited by applicant]
US 5225539A · Winter · 1993 [cited by applicant]
US 5530101A · Queen et al. · 1996 [cited by applicant]
US 5573920A · Randle · 1996 [cited by applicant]
US 5585089A · Queen et al. · 1996 [cited by applicant]
US 5591639A · Bebbington · 1997 [cited by applicant]
US 5601819A · Wong et al. · 1997 [cited by applicant]
US 5622929A · Willner et al. · 1997 [cited by applicant]
US 5624821A · Winter et al. · 1997 [cited by applicant]
US 5658759A · Bebbington · 1997 [cited by applicant]
US 5824805A · King et al. · 1998 [cited by applicant]
US 5834597A · Tso et al. · 1998 [cited by applicant]
US 5859205A · Adair et al. · 1999 [cited by applicant]
US 5879936A · Bebbington et al. · 1999 [cited by applicant]
US 5891693A · Bebbington et al. · 1999 [cited by applicant]
US 5981216A · Kenten et al. · 1999 [cited by applicant]
US 6130237A · Denny et al. · 2000 [cited by applicant]
US 6214345B1 · Firestone et al. · 2001 [cited by applicant]
US 6407213B1 · Carter et al. · 2002 [cited by applicant]
US 6624821B1 · Shin et al. · 2003 [cited by applicant]
US 6881557B2 · Foote · 2005 [cited by applicant]
US 7498298B2 · Doronina et al. · 2009 [cited by applicant]
US 7659241B2 · Senter et al. · 2010 [cited by applicant]
US 7968687B2 · McDonagh et al. · 2011 [cited by applicant]
US 20050238649A1 · Doronina et al. · 2005 [cited by applicant]
US 20060074008A1 · Senter et al. · 2006 [cited by applicant]
US 20090018086A1 · Doronina et al. · 2009 [cited by applicant]
US 20090111756A1 · Doronina et al. · 2009 [cited by applicant]
US 20100158909A1 · McDonagh et al. · 2010 [cited by applicant]
US 20180092984A1 · Lewis et al. · 2018 [cited by applicant]
US 20180154018A1 · Yurkovetskiy · 2018 [cited by examiner]
US 20190343828A1 · Jeffrey · 2019 [cited by examiner]
EP 0216846 · 1987 [cited by applicant]
EP 0323997 · 1989 [cited by applicant]
EP 0338841 · 1989 [cited by applicant]
EP 0629240 · 1994 [cited by applicant]
WO WO198704462 · 1987 [cited by applicant]
WO WO198912624 · 1989 [cited by applicant]
WO WO199100360 · 1991 [cited by applicant]
WO WO199205793 · 1992 [cited by applicant]
WO WO199208802 · 1992 [cited by applicant]
WO WO199222653 · 1992 [cited by applicant]
WO WO199317715 · 1993 [cited by applicant]
WO WO2006036291 · 2006 [cited by applicant]
WO WO2018191660 · 2018 [cited by applicant]
WO WO2019148089 · 2019 [cited by applicant]
WO WO2019195665 · 2019 [cited by applicant]
WO WO2019195665A1 · 2019 [cited by examiner]
Michael J. Birrer, Kathleen N. Moore, Ilaria Betella, Richard C. Bate. “Antibody-Drug Conjugate-Based Therapeutics: State of the Science” JNCI J Natl Cancer Inst, Mar. 11, 2019 111(6): djz035.doi: 10.1093/jnci/djz035 (Y… [cited by examiner]
Anastasia Constantinidou, Constantinos Alifieris, Dimitrios T. Trafalis, “Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy”, Pharmacology & Therapeutics, vol. 194, F… [cited by examiner]
Liu, Boning et al. “Acid-induced aggregation propensity of nivolumab is dependent on the Fc.” mAbs vol. 8,6 (2016): 1107-17. doi: 10.1080/19420862.2016.1197443 (Year: 2016). [cited by examiner]
Kevin O. Saunders “Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life” Front. Immunol., Jun. 6, 2019, vol. 10—2019. doi: 10.3389/fimmu.2019.01296 (Year: 2019). [cited by examiner]
Powels et al. (Nature Nov. 27, 2014, 515:558-562) (Year: 2014). [cited by examiner]
Al-Lazikani et al., “Standard conformations for the canonical structures of immunoglobulins,” [cited by applicant]
Chari et al., “Immunoconjugates containing novel maytansinoids: promising anticancer drugs,” [cited by applicant]
Chothia et al., “Canonical structures for the hypervariable regions of immunoglobulins,” [cited by applicant]
Clackson et al., “Making antibody fragments using phage display libraries,” [cited by applicant]
Collins et al., “Product review: avelumab, an anti-PD-L1 antibody,” [cited by applicant]
Davies et al., “Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII,” [cited by applicant]
De La Cruz Edmunds et al., “Development of transfection and high-producer screening protocols for the CHOK1SV cell system,” [cited by applicant]
Dubowchik et al., “Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs,” [cited by applicant]
Ghetie et al., “Multiple roles for the major histocompatibility complex class I-related receptor FcRn,” [cited by applicant]
Ghetie et al., “Transcytosis and catabolismof antibody,” [cited by applicant]
Hieter et al., “Evolution of human immunoglobulin kappa J region genes,” [cited by applicant]
Hinton et al., “Engineered human IgG antibodies with longer serum half-lives in primates,” [cited by applicant]
Honegger et al., “Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool,” [cited by applicant]
Idusogie et al., “Engineered antibodies with increased activity to recruit complement,” [cited by applicant]
Iwahashi et al., “CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity,” [cited by applicant]
Jefferis et al., “Human immunoglobulin allotypes: possible implications for immunogenicity,” [cited by applicant]
Johnson et al., “Anti-tumor activity of CC49-doxorubicin immunoconjugates,” [cited by applicant]
Kohler et al., “Continuous cultures of fused cells secreting antibody of predefined specificity,” [cited by applicant]
Kontermann et al., “Complement recruitment using bispecific diabodies,” [cited by applicant]
Kostelny et al., “Formation of a bispecific antibody by the use of leucine zippers,” [cited by applicant]
Lau et al., “Conjugation of doxorubicin to monoclonal anti-carcinoembryonic antigen antibody via novel thiol-directed cross-linking reagents,” [cited by applicant]
Lau et al., “Novel doxorubicin-monoclonal anti-carcinoembryonic antigen antibody immunoconjugate activity in vitro,” [cited by applicant]
Lazar et al., “Engineered antibody Fc variants with enhanced effector function,” [cited by applicant]
Lefranc et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,” [cited by applicant]
Lund et al., “Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains,” [cited by applicant]
MacCallum et al., “Antibody-antigen interactions: contact analysis and binding site topography,” [cited by applicant]
Marks et al., “By-passing immunization. Human antibodies from V-gene libraries displayed on page,” [cited by applicant]
Martin et al., “Modeling antibody hypervariable loops: a combined algorithm,” [cited by applicant]
Mattila et al., “Extensive allelic sequence variation in the J region of the human immunoglobulin heavy chain gene locus,” [cited by applicant]
Nakada et al., “Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads,” [cited by applicant]
Neville et al., “Enhancement of immunotoxin efficacy by acid-cleavable cross-linking agents utilizing diphtheria toxin and toxin mutants,” [cited by applicant]
Niwa et al., “Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma,” [cited by applicant]
Okazaki et al., “Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa,” [cited by applicant]
Pascalis et al., “Grafting of “abbreviated” complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody,” [cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2020/054037, dated Feb. 10, 2021, 27 pages. [cited by applicant]
PCT Invitation to Pay Additional Fees in International Appln. No. PCT/US2020/054037, dated Feb. 22, 2021, 22 pages. [cited by applicant]
Queen et al., “Cell-type specific regulation of a kappa immunoglobulin gene by promoter and enhancer elements,” [cited by applicant]
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” [cited by applicant]
Sau et al., “PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer,” [cited by applicant]
Sela-Culang et al., “The structural basis of antibody-antigen recognition,” [cited by applicant]
Shields et al., “High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R,” [cited by applicant]
Shields et al., “Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity,” [cited by applicant]
Shin et al., “Physical map of the 3′ region of the human immunoglobulin heavy chain locus: clustering of autoantibody-related variable segments in one haplotype,” [cited by applicant]
Shopes, “A genetically engineered human IgG mutant with enhanced cytolytic activity,” [cited by applicant]
Smith et al., “Addition of a mu-tailpiece to IgG results in polymeric antibodies with enhanced effector functions including complement-mediated cytolysis by IgG4,” [cited by applicant]
Storz, “Intellectual property issues of immune checkpoint inhibitors,” [cited by applicant]
Tamura et al., “Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only,” [cited by applicant]
Tan et al., “Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab,” [cited by applicant]
Thorpe et al., “New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo,” [cited by applicant]
Thorpe et al., “The preparation and cytotoxic properties of antibody-toxin conjugates,” [cited by applicant]
Tutt et al., “Trispecific F(ab′)3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells,” [cited by applicant]
Umana et al., “Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity,” [cited by applicant]
UniProt Accession No. Q9NZQ7.1, “RecName: Full=Programmed cell death 1 ligand 1; Short=PD-L1; Short=PDCD1 ligand 1; Short=Programmed death ligand 1; AltName: Full=B7 homolog 1; Short=B7-H1; AltName: CD_antigen=CD274; Fl… [cited by applicant]
Vajdos et al., “Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis,” [cited by applicant]
Wright et al., “Effect of glycosylation on antibody function: implications for genetic engineering,” [cited by applicant]
Rudnick, S. I. et al., “Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors”, Cancer research, vol. 71, No. 6, Mar. 15, 2011, pp. 2250-2259. [cited by applicant]